Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3
| CTXR Stock | USD 0.13 0.04 23.53% |
Slightly above 58% of all Citius Pharmaceuticals' retail investors are looking to take a long position. The analysis of overall sentiment of trading Citius Pharmaceuticals stock suggests that some investors are interested at this time. Citius Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Citius Pharmaceuticals. Many technical investors use Citius Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Citius |
Filed transaction by Citius Pharmaceuticals Director, 10 Percent Owner, Officer Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Citius Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Citius Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Citius Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Citius Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Citius Pharmaceuticals Fundamental Analysis
We analyze Citius Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Citius Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Citius Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Citius Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Citius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Citius Pharmaceuticals Related Equities
| MCRB | Seres Therapeutics | 15.58 | ||||
| HOOK | Hookipa Pharma | 6.51 | ||||
| FBIO | Fortress Biotech | 4.35 | ||||
| TERN | Terns Pharmaceuticals | 1.40 | ||||
| ABOS | Acumen Pharmaceuticals | 0.42 | ||||
| ARDX | Ardelyx | 1.13 | ||||
| IBRX | Immunitybio | 1.18 | ||||
| DAWN | Day One | 2.19 | ||||
| BLRX | BioLineRx | 3.57 | ||||
| LXRX | Lexicon Pharmaceuticals | 5.81 | ||||
| INZY | Inozyme Pharma | 6.05 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| MREO | Mereo BioPharma | 9.14 |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.